ArticlePloS one2026
Spiramycin (SPR) antibiotics degradation with WO3 photocatalyst and ML XGBoost model for process parameters screening.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intensification of worldwide urbanization and industrial growth has led to a rise in the release of toxic substances into the environment. Antibiotics are widely used as human medicine and animal husbandry, for example annual global consumption (106 kg) of amoxicillin is 11.8, sulfamethoxazole is 2.0, tetracycline is 0.5 and spiramycin is 0.3 etc., therefore, they are often found in surface water and wastewater, thus possess a threat both to human and eco health. Photocatalytic technology can efficiently eliminate highly hazardous, low-concentration, and hard-to-treat contaminant, and tungsten trioxide (WO3) serves as a highly promising alternative photocatalyst. Evaluating the effectiveness of WO3 in photocatalytic decomposition through traditional techniques is resource intensive and complex. Consequently, in this study experimental results are applied for modeling and optimizing the operational parameters on photocatalytic decomposition of spiramycin, an emerging antibiotic contaminant using WO3 as photocatalyst. Three experimental parameters (photoreactor solution pH, WO3 concentration and spiramycin (SPR) initial concentration) were chosen to gather preliminary information. The influencing interaction effects and optimal parameters values were determined by using a machine learning technique of XGBoost employing a data set of 45 dataset points obtained under 3 parametric effects. The model achieved an R2 value of 0.983 and 0.992 on test and training data, respectively. SHAP (SHapley Additive exPlanations) analysis was utilized to elucidate the prediction outcomes, uncovering the importance and influence patterns of the input parameters. The degradation rate of SPR approached ~87.6% under optimal conditions of pH value of 5.0, WO3 concentration of 0.125g/l and pollutant concentration of 0.15 g/l, respectively. In addition, the applied ML method revealed that the most influencing parameter is the reactor solution pH value followed by pollutant concentration on the decomposition of SPR antibiotic. Moreover, we conducted experiments to investigate the role of oxidizing species. Our findings indicate that primarily hydroxyl radicals (OH•) followed by photoinduced holes (h+s) and hydrogen peroxide (H2O2), play significant roles in the breakdown of model contaminant. We also studied the reaction kinetics and proposed the photocatalytic mechanism based on the obtained results. As a study outcome, the XGBoost model exhibits great accuracy and strength, suggesting that machine learning holds considerable practical promise and worth in forecasting the degradation emerging pollutants via photocatalysts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.